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Background: Thymectomy is an effective and accepted treatment for myasthenia gravis,
but thymectomy for ocular myasthenia gravis (Osserman stage I) is controversial.
Objective:  To assess the efficacy and propriety of thymectomy for the treatment of
ocular myasthenia gravis.
Methods:  We conducted a review and follow-up of all patients who had thymecto-
my for the treatment of ocular myasthenia gravis between 1970 and 1998 at the
University of California, Davis, Medical Center, and the University of Rome, “La
Sapienza,” Rome, Italy. Patient response to thymectomy was categorized as follows:
cured, patients who became symptom-free and required no further medication;
improved, patients who required less medication and whose symptoms were less
severe; unchanged, patients whose symptoms and medications were the same;
worse, patients who had more severe symptoms, needed more medication, or died.
Results:  Sixty-one patients (mean age 37 years; range 14–73 years) were fol-
lowed up for a mean duration of 9 years (range 0.5–29 years). Ocular myasthenia
gravis with mixed and cortical thymomas, stages I to IV, occurred in 12 patients,
and ocular myasthenia without thymomas occurred in 49 patients. Transsternal
thymectomy (n = 55) and transcervical thymectomy (n = 6) resulted in cure in 31
(51%) patients, improvement in 12 (20%) patients, no change in 16 (26%)
patients, and worsening of symptoms (including 1 postoperative death) in 2
patients. Patient outcomes were statistically independent of the duration of pre-
operative symptoms (mean 9.5 months), patient age, or the presence or absence
of thymoma. In patients with ocular myasthenia, 70% were cured or improved
after thymectomy; in the subgroup of patients with ocular myasthenia and thy-
moma, 67% were cured or improved.
Conclusion:  Thymectomy is an effective and safe treatment for patients with ocu-
lar myasthenia gravis.
Thymectomy has a generally accepted beneficial role in the treatmentof myasthenia gravis (MG), but controversy persists regarding theindications and timing for operations. Since thymectomy was firstdescribed in association with MG by Sauerbruch1 in 1912 and forthe treatment of MG by Blalock and associates2 in 1939, therapeuticadvances have included the use of anticholinesterase drugs, corti-
costeroids, and other immunosuppressive medications. These adjuncts to thymecto-
my, better diagnostic tools, and improved critical care support have progressively
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improved patient outcomes. However, these advances have
also complicated defining the role of thymectomy.
Prospective studies have been difficult to design and inter-
pret because of the variability of medical treatment and the
natural history of the disease itself. 
A survey of neurologists with special interest in MG in
1990 showed that most of them believed thymectomy to be
indicated in patients with thymomas and in selected cases of
generalized MG. However, they rarely favored thymectomy
to treat purely ocular MG in the absence of thymoma,3 like-
ly because of reluctance to recommend a major operation
for symptoms such as diplopia and ptosis. Some surgeons4
have countered this argument by advocating transcervical
thymectomy as a less morbid and equally effective tech-
nique of resection as compared with the traditional
transsternal approach. To date, a consensus has not been
reached about the specific indications for surgery in the
treatment of MG with symptoms limited to the eyes.
Opinion also varies as to whether ocular MG is a dis-
tinct disease or one end of a disease spectrum with severe
generalized MG as the other end.5 Because no definitive,
prospective, randomized study has been conducted to
resolve this issue, one must rely on sporadic reports with
their inherent biases as well as on one’s own experience.
We have observed that the ocular symptoms of MG seri-
ously impair patients’ lifestyles, that there are serious side
effects of the long-term use of potent drugs, and that pro-
gression to generalized MG is a bad outcome. We there-
fore have used thymectomy in MG even when symptoms
have been purely ocular. We now report the results from
two institutions in which thymectomy has been used to
treat ocular MG.
Patients and Methods
Between 1970 and 1998, 61 patients underwent thymectomy for
ocular MG (Osserman stage I), 54 patients at the University of
Rome “La Sapienza” and 7 patients at the University of California,
Davis, Medical Center. The hospital course of each of these
patients was reviewed retrospectively. All patients had been
referred from neurologists who had a specific interest and exper-
tise in the management of MG. All patients with purely ocular
symptoms who were referred for thymectomy were accepted for
surgery. The diagnosis of ocular MG was made clinically with a
TABLE 1. Distribution of stage, cell type, and clinical outcome of patients with ocular myasthenia gravis (MG) 
and thymoma
Patient Duration of Thymoma Response of Cause of Years
(age [y], sex) symptoms stage Histology ocular MG death postop
1 (54, M) 1 III Mixed Cured Recurrence 4
2 (35, M) 1 IV Cortical Cured Recurrence 4
3 (25, M) 5 I Cortical Operative death Bleeding 0
4 (27, F) 4 IV Mixed Improved Recurrence 7
5 (48, M) 3 III Cortical Improved Recurrence 5
6 (22, F) 1 I Mixed Stable Alive 10
7 (36, F) 1 II Cortical Cured Alive 6
8 (65, M) 4 II Cortical Improved Alive 5
9 (40, M) 2 II Cortical Improved Alive 5
10 (42, M) 24 I Cortical Cured Myocardial infarction 1
11 (64, M) 8 II Cortical Stable Alive 4
12 (61, F) 2 I Cortical Stable Alive 4
TABLE 2. Summary of literature demonstrating lack of consensus for optimal treatment of ocular MG
Studies Year No. of patients Conclusions
Schumm et al7 1985 18 with ocular MG Surgery for patients who do not respond to medical 
therapy
Papatestas et al8 1987 2062 with MGa Advantage to thymectomy seen in all stages 
962 had thymectomies, 12 with ocular MG
Evoli et al9 1988 247 with MG, 24 with ocular MG Thymectomy is not effective in patients with ocular MG
Hatton et al10 1989 11 with ocular MG Results of surgical and nonoperative treatment are equal
Nakamura et al13 1996 22 with ocular MG Clear benefit of surgery
Masaoka14 1996 375 with MG, 40 with ocular MG Thymectomy is effective treatment for both MG and 
ocular MG
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detailed history and physical examination in all patients by an aca-
demic neurologist specializing in MG. Patients with only ocular
symptoms were included. Adjunctive testing was also performed in
all patients, including a combination of jitter testing, electromyo-
graphic testing, and acetylcholine receptor antibody assay.
Transsternal resections were done in 55 patients, including 17
full sternotomies, 38 partial sternal splits, and 6 transcervical
resections. There were 30 women (49%) and 31 men (51%); mean
age was 37 years (range 14–73 years; standard deviation ±15
years) (Figure 1). The records of all patients were reviewed. All
surviving patients continue to be closely monitored by the princi-
pal neurologist. Additional updating was achieved through tele-
phone interviews in cases in which more than 1 year had passed
since the last visit. Preoperative management of the MG, duration
of symptoms before the operation, pathologic findings of the
resected specimens, and the immediate and long-term sequelae of
operations were evaluated.
Definitions of Response 
Patients who were symptom-free and did not require any further
medication were designated as cured. Those who became less
symptomatic than preoperatively or who needed less medication
were categorized as improved. Patients whose postoperative symp-
toms and medications were similar to those experienced preopera-
tively were considered unchanged. Patients whose ocular symp-
toms or progression to generalized MG became exacerbated or
who died as a result of the operation were categorized as worse.
Data were compared and analyzed for statistical significance by
a Mann-Whitney rank sum test.
Results
All patients who underwent thymectomy without thymo-
mas lived. The single operative complication leading to
death in the study was postoperative bleeding in a patient
with a thymoma. Two minor complications (3.3%) of
pneumothorax, which necessitated chest tube placement,
occurred after thymectomy. No postoperative wound com-
plications were encountered.
Follow-up was complete in 100% of the patients. The
mean duration of follow-up was 9 years (range 6 months–29
years). Thirty-one (51%) patients were cured (mean of fol-
low-up 11 years; range 6 months–29 years). The condition
of 12 (20%) patients was improved (mean follow-up 8
years; range 9 months–25 years). The condition of 16 (26%)
patients was unchanged (mean follow-up 9 years; range 3-
23 years). Two patients, including the 1 who died as a result
of the operation, were in worse condition. Six patients sub-
sequently died of unrelated causes (Figure 2).
Twelve (20%) patients had thymomas (stage I, 4 patients;
stage II, 4 patients; stage III, 2 patients; and stage IV, 2
patients) (Table 1). Except for the single operative death, the
outcome of patients with thymomas was similar to that of
the whole group. Four patients died as a result of thymoma
recurrence (mean 5.5 years; range 4–7 years).
Two patients received corticosteroids only preoperative-
ly. All other patients received anticholinesterase drugs pre-
operatively and 12 patients received both. The average dura-
tion of symptoms before surgery was 9.5 months (standard
deviation ±10 months; range 1–60 months).
Patients who were cured or improved after thymectomies
were compared with those who had no benefit from thymec-
tomy or became worse. All groups were similar with regard
to age, duration of symptoms, presence of thymoma, and
surgical approach.
General Thoracic Surgery Roberts et al
Figure 1. Distribution of patients with ocular MG.
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Discussion
Ocular MG is not a life-threatening illness and some natural
remissions clearly occur without surgery. Oosterhuis6 report-
ed a natural remission rate of 30% in cases of ocular MG dur-
ing the course of 15 years. Few large long-term studies have
been conducted in patients undergoing thymectomy for pure-
ly ocular MG. Whether the route is transsternal or transcervi-
cal, thymectomy must be considered a major operation.
Treatment of generalized MG with thymectomy has been
scrutinized in the same way as thymectomy for ocular MG.
However, the tremendous variability in diagnosis, medical
treatment, and length of time before referral to a surgeon has
made ocular MG difficult to study. Lack of a good database
and reliance on referring neurologists for most follow-up
information have been cited for the variability of the few pub-
lished studies. In addition, because of the nuisance nature of
the symptoms, patients themselves may not be reliable in ret-
rospect for detailing the duration and intensity of their symp-
toms many months to years after the operation.
During the past 2 decades, conflicting conclusions have
been reported about the best way to manage ocular MG.
Schumm and colleagues7 used an outcome scoring system
and reported that all 18 of their patients treated with
thymectomy had some improvement and that none had pro-
gression to generalized MG. Even though only 3 (17%) of
their patients responded with full remission, the authors
nevertheless recommended thymectomy to treat patients
whose ocular MG failed to improve after 6 months of non-
operative management. Papatestas and associates8 reported
on 2062 patients with MG, including 962 patients who had
thymectomies and 12 who had thymectomies for the treat-
ment of ocular MG. They concluded that good outcomes
from thymectomies for all stages of MG were most likely
when operations were done early and when the patients did
not have thymomas.
Evoli and associates9 reported on 247 patients who under-
went thymectomy for all stages of MG. After analysis of their
data, they concluded that thymectomy is not effective in
patients with purely ocular symptoms. However, they did not
specifically evaluate the presence or absence of thymoma and
duration of symptoms before treatment in the ocular subgroup.
Their average duration of symptoms before surgery for all
stages of MG was 15.9 months in those with a thymoma and
37.6 months in those without a thymoma (range 1–312
months). Hatton and coworkers10 reported on 11 patients treat-
ed in a 15-year period and concluded that the therapeutic out-
come of thymectomy for ocular MG was the same as that of
nonoperative management. They also did not discuss the
elapsed time from development of symptoms to operation.
These data, combined with those of others,11,12 fueled the
belief that thymectomy should not be recommended for the
treatment of ocular MG.3 Proponents of thymectomy in the
treatment of ocular MG, such as Nakamura and colleagues,13
whose 22 patients had a postoperative remission rate of about
33%, and Masaoka and associates,14 who unequivocally advo-
cated thymectomy for the treatment of ocular MG, recom-
mended radical thymectomy and found the duration of symp-
toms before the operation to be a predictor of outcome. Their
mean duration of preoperative symptoms in patients not hav-
ing a thymoma was 45.6 months (range 0–348 months [mean
Figure 2. Response to thymectomy.
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18.6 months; range 0–192 months in patients with a thymo-
ma]). Table 2 summarizes previously published information. 
Analysis of our data demonstrated no difference in duration
of preoperative symptoms when comparing patients benefiting
from surgery with those not benefiting from surgery. However,
our mean duration from diagnosis to surgery was 9.5 months,
which is much lower than that reported in other studies we
examined. This shorter time span may help to explain why our
results seemed better than those of other groups, even in stud-
ies that favored thymectomy for ocular MG.
We believe the evidence favors the treatment of ocular MG
with thymectomy. Seventy-one percent of our patients with
ocular MG were cured (51%) or improved (20%) after
thymectomies. Even if we assume a natural remission rate of
somewhere between 10% and 30%, the 51% cure rate and
additional 20% improvement rate in our study cannot be dis-
counted and must be attributed to a surgical effect. None of
the patients with ocular MG without thymoma had adverse
sequelae from their operations. The patient who died postop-
eratively had a thymoma, which by itself would have been an
indication for the operation.
On the basis of previous reports about the adverse
effect of thymoma on the outcome of thymectomy, we
expected less favorable results among our patients having
ocular MG with thymomas. Sixty-seven percent of the 12
patients in our thymoma subgroup were cured (33%) or
improved (33%), but this percentage was not statistically
significant (P < .39) when compared with the percentage
of patients cured in the ocular MG group without thymo-
ma. However, the number of patients in our thymoma sub-
group was not large. Possibly a larger study of patients
with ocular MG and thymomas could provide more defin-
itive data, but such a study will require a prospective, ran-
domized, cooperative trial. 
The relation between thymoma and MG is a fascinating
and incompletely understood issue in tumor biology. At
least two factors may explain why our results were better
than previous ones. First, our collective patients were oper-
ated on soon after the onset of symptoms. Second, after the
operation, neurologists did not hesitate to withdraw all
drugs if gradual improvement to resolution of symptoms
occurred. This certainly contributed to our high cure rate.
Some surgeons have cited neurologists’ reluctance to with-
draw medication in symptom-free patients as a contributing
factor in lower cure rates. Maintenance of drug therapy is
based on the belief that continuation of some drugs may
help prevent recurrence of MG symptoms. There is some
immunologic evidence that thymectomy in the presence of
thymoma may exacerbate MG symptoms and that drugs
should be continued regardless of symptomatic improve-
ment.15,16 Good evidence exists to suggest that, in the
future, specific immunotherapy will be a crucial part of the
treatment of MG.
However, according to our data, in the majority of patients
thymectomy affords a chance of complete remission, improve-
ment in symptoms, decreasing medication dosages, and the
potential of halting progression to generalized MG. Even the
16 patients in our group whose conditions we categorized as
unchanged may have actually received some benefit given the
overall very low rate of progression to generalized MG
(1.6%). With only 3.2% of patients in worse condition and an
operative mortality and serious complication rate of 1.6%,
there is little risk in pursuing surgical management. 
Thymectomy is a major operation whether done
through the neck or the sternum. The optimal technique is
the subject of many past and ongoing studies and is
beyond the scope of our article. Our rationale for perform-
ing thymectomies was based on the observation that the
symptoms of ocular MG do interfere significantly with the
lifestyle of patients and on the fact that significant risks
and costs are associated with long-term nonoperative treat-
ment. Inasmuch as one of our patients died of postopera-
tive complications, one could argue that thymectomy is not
entirely safe. However, this single death occurred in a
patient who had a thymoma for which thymectomy would
have been recommended even without MG. Because no
deaths or major complications occurred among patients
who had pure ocular MG without thymomas, the argument
seems less sound.
If we analyze our patients without thymomas, we have a
subset of patients with a 71% rate of improvement or cure
and a 0% operative mortality. On the basis of our results, we
think thymectomy should be considered for patients with
ocular MG in all age groups if there is a reasonable life
expectancy and comorbidities are not significant. Approach
by the transsternal or transcervical route is safe and will
likely be effective in the majority of patients, regardless of
age or preoperative duration of symptoms.
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year. If the disease becomes generalized during that period, then
thymectomy is in order, but that occurs in only 15% of patients
who still have only ocular symptoms after 1 year. Another 20%
have experienced remission during that year. In the series from
Mount Sinai in New York reported by Papatestas, 300 patients had
ocular MG and no thymoma, only 3 of whom were treated with
thymectomy. One of the 3 went into remission and another died,
illustrating the chilling effect of an early death after elective, even
controversial, surgery. The 1 death in the operative series reported
today occurred in a patient with thymoma who would have been
operated on for that reason alone and should not be a vote against
thymectomy for ocular MG. Although it is true that powerful drugs
such as pyridostigmine bromide (Mestinon), prednisone, and aza-
thioprine may and do cause adverse effects in 50% or so of
patients, the drugs had to be stopped in only 1% to 14% of patients
in a series reported from The Netherlands. 
I would like to say a word about operative technique. The most
important thing is complete removal of the thymus gland. My own
preference was for sternotomy. I thought I could do the best job
that way. If others can accomplish complete thymectomy using a
cervical or even thoracoscopic approach in patients without thy-
moma, well and good. I do not believe Jaretzky’s so-called maxi-
mal thymectomy is necessary.
In summary, I find the information interesting but not scientifi-
cally persuasive. What Dr Roberts has described is a phase II study
demonstrating feasibility. What we need is a phase III study so that
the best treatment of ocular MG can really be identified. 
Dr Roberts. Thank you very much, Dr Mark. I certainly con-
cur with your comments. You have given an elegant discussion
of the more detailed problems that face the treatment of patients
with MG. Chief among them is the absence of any prospective,
randomized study. Until such a study can be organized, we will
have to rely on sporadic reports from various studies, but cer-
tainly your points are valid. What our report did demonstrate is
that surgical treatment is safe, with a low complication rate and
a very low mortality rate, and still provides these patients with a
70% chance of cure or improvement. The rate of progression of
10% to 20% to generalized MG is probably pretty low. In our
group it was virtually 0%. 
I appreciate your comments and I look forward to a greater con-
sensus on the treatment of this disease. 
Dr Thomas W. Rice (Cleveland, Ohio). This study covered a
large span of time and it was performed at two different institu-
tions. How did you diagnose MG? How did you define ocular MG?
How did you exclude diffuse or truncal MG? 
Dr Roberts. Diagnosis is another of the difficulties in this
disease. If the patient is having a “good day,” when he or she
feels a little lethargic or feels great, the patient may claim to have
no other symptoms. That may change the diagnosis. All the
patients were referred by neurologists who specialize in the diag-
nosis and treatment of MG. A combination of methods was used,
largely assessment of symptoms, both ptosis and diplopia. There
was no specific grading system within those two. There was
some variability in provocative testing and electromyography. 
Dr Rice. Are you saying that the majority were categorized just
by their symptoms?
Dr Roberts. They were categorized by their symptoms and by
provocative testing.
in the treatment of myasthenia gravis: report of 247 patients. J Neurol.
1988;235:272-6.
10. Hatton PD, Diehl JT, Daly BDT, Rheinlander HF, Johnson H,
Schrader JB, et al. Transsternal radical thymectomy for myasthenia
gravis: a 15-year review. Ann Thorac Surg. 1989;47:838-40.
11. Kay R, Lam S, Wong KS, Wang A, Ho J. Response to thymectomy in
Chinese patients with myasthenia gravis. J Neurol Sci. 1994;126:84-7.
12. Ali SM, Abbas F, Sonawalla A, Altafullah I, Sheikh H. Role of
thymectomy in myasthenia gravis. J Pak Med Assoc. 1992;42:107-11.
13. Nakamura H, Taniguchi Y, Suzuki Y, Tanaka Y, Ishiguro K, Fukuda M,
et al. Delayed remission after thymectomy for myasthenia gravis of
the purely ocular type. J Thorac Cardiovasc Surg. 1996;112:371-5.
14. Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M, et
al. Extended thymectomy for myasthenia gravis patients: a 20-year
review. Ann Thorac Surg. 1996;62:853-9.
15. Somnier FE. Exacerbation of myasthenia gravis after removal of thy-
momas. Acta Neurol Scand. 1994;90:56-66.
16. Kuroda Y, Oda K, Neshige R, Shibasaki H. Exacerbation of myasthe-
nia gravis after removal of a thymoma having a membrane phenotype
of suppressor T cells. Ann Neurol. 1984;15:400-2.
Discussion
Dr James B. D. Mark (Stanford, Calif). Dr Roberts has pre-
sented some interesting and provocative material. It now behooves
us to see just how compelling his argument is. What he wants us to
do is to seriously consider thymectomy as the primary treatment
for ocular MG, a position quite contrary to the prevailing opinion
in this country. Let us dissect his argument.
This report concerns 61 patients operated on over a 20-year
period in two institutions, one in California and one in Italy, both
locations well known for wine and joie de vivre. The first thing that
strikes the eye is that 54 of the patients were operated on at “La
Sapienza” in Rome and 7 at UC Davis, suggesting strongly that
there may be a bias toward thymectomy for ocular MG outside the
United States and very little enthusiasm for it in this country. A
review of the literature reinforces this idea. In any study such as
this, it is impossible to know how many patients with ocular MG
were never referred for surgical opinion, which in this study was
tantamount to surgical treatment.
Why do these authors operate on patients with MG while most
groups do not? Twelve of 61 patients had thymoma. No one argues
against operation in those patients, but how about the others? The
reasons offered by the authors and others are to alleviate the symp-
toms of ocular MG, to avoid the adverse effect of drugs used to
treat MG, to accelerate the onset of remission, to prevent progres-
sion to generalized MG, and to decrease mortality. 
How compelling are the arguments? Ocular MG affects the
extraocular muscles and the levator palpebrae leading to diplopia
and ptosis. Diplopia can be palliated by patching one eye at a time.
No binocular vision, no diplopia, as the old saying goes. Ptosis is
a bit more of a problem, but a relatively minor palliative operation,
surely not as invasive or risky as thymectomy, is available for that
problem. The worst symptoms are usually in the first year after
onset, so most treatment does not have to last forever. Twenty per-
cent to 50% of patients with ocular MG have a remission without
an operation. In the absence of a controlled study, it is unlikely that
one can prove that surgery hastens remission or results in more
remissions than medical treatment. Essentially all neurologists in
this country recommend medical treatment of ocular MG for 1
year before surgical treatment is considered. In the present study,
91⁄2 months was the preoperative period—not very different from 1
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which patients were monitored, or were they operated on at the
time of referral?
Dr Roberts. All of the patients in both groups were operated on
after they were referred by the neurologist, but the neurologist
largely determined when the operation would be done by the tim-
ing of that referral. On average, though, surgery was not consid-
ered before 6 months.
Dr Richard Whyte (Stanford, Calif). Can you describe the
specific indications for the referral for the operation, or did the
neurologist, particularly those in Italy, just say, “If the patients
have ocular MG, they should have an operation?”
Dr Roberts. That is largely true, and I think that is why the
Italian group had as large a number of patients as they did. Our
patients were referred by a single neurologist who believes that
ocular MG that does not resolve in less than 6 months with anti-
cholinesterase therapy should be treated by thymectomy. That
essentially was the indication for operation.
General Thoracic Surgery Roberts et al
Dr Rice. Is it true that electromyography was not used?
Dr Roberts. The Italian group actually did use electromyogra-
phy in all but a couple of their patients.
Dr Rice. In how many of the patients did the disease progress?
Dr Roberts. One.
Dr Rice. Did you subclassify thymomas into cortical or
medullary?
Dr Roberts. Yes. All but 4 were cortical; I believe those 4 were
of a mixed subtype.
Dr Rice. Did that predict stage or survival?
Dr Roberts. No, there were only 4 such cases. The predictor of
death was the stage of disease, and all patients with stage III or IV
MG died within 5 to 7 years.
Dr John Chen (Honolulu, Hawaii). The timing of thymoma
for ocular MG has been somewhat controversial. You did not
specify at what point you did the operation. During your review
of these patient records, did you encounter a time period in
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